Here, we used four MET superfamily TKIs to explore their therapeutic effects on pancreatic cancer: BMS777607, PHA665752, INCB28060 (capmatinib; INC280), and Tivantinib (ARQ 197). Here, MET is linked to pancreatic neoplasm.